정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
---|---|---|---|---|---|---|---|---|---|---|---|
184 | Completed | This is a Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19 | Vaccine | Biological: Vaccine for intramuscular injection Other: Placebo comparator (without active ingredient) for intramuscular injection |
Phase 2 | Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products | OTHER_GOV | 400 | All | 18 Years ~ 60 Years | Federal State Budgetary Educational Institution of Higher Education Kirov State Medical University of the Ministry of Health of Russia, Kirov, Russian Federation FSBSI Chumakov FSC R&D IBP RAS, Moscow, Russian Federation FGBUZ MSCh No. 163 FMBA of Russia, Novosibirsk, Russian Federation Eco-Safety Scientific Research Center LLC, Sankt Peterburg, Russian Federation Center for Family Medicine Joint Stock Company (CSM JSC), Yekaterinburg, Russian Federation |
183 | Active, not recruiting | This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19) | SARS-CoV-2 Infection | Biological: CT-P59 | Phase 1 | Celltrion | INDUSTRY | 18 | All | 18 Years ~ 60 Years | Incheon Medical Center, Incheon, Korea, Republic of |
182 | Recruiting | Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection | Covid19 | Drug: Thymalfasin | Phase 2 | Rhode Island Hospital | OTHER | 80 | All | 18 Years | The Miriam Hospital, Providence, Rhode Island, United States |
181 | Recruiting | Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients | COVID-19 | Drug: Thymalfasin | Phase 2 | Inova Health System, Davita Clinical Research, Clinical Research Consultants, LLC | OTHER | 240 | All | 60 Years | Clinical Research Consultants, Kansas City, Kansas, United States |
180 | Completed | Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19 | Coronavirus Disease 2019 | Biological: Tigerase® and best available care Other: Best available care |
Phase 3 | AO GENERIUM | INDUSTRY | 100 | All | 18 Years | City Clinical Hospital #15, Moscow, Russian Federation I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation City Clinical Hospital #51, Moscow, Russian Federation City Clinical Hospital #52, Moscow, Russian Federation N.V. Sklifosovsky Scientific Research Institute of First Aid, Moscow, Russian Federation Siberian State Medical University (SibMed), Moscow, Russian Federation |
179 | Recruiting | Timing of Corticosteroids in COVID-19 | Corticosteroids | Drug: Early-Dexamethasone Drug: Late-Dexamethasone |
Phase 4 | ClinAmygate | OTHER | 450 | All | 18 Years | Asalam, Maadi, Cairo, Egypt |
178 | Completed | To Assess the Safety, Tolerability and Pharmacokinetic Properties of Niclosamide Injectable (DWRX2003) Which is the Treatment of COVID-19 in Healthy Volunteers. | Covid19 | Drug: DWRX2003, 288mg Drug: DWRX2003, 432mg Drug: DWRX2003, 672mg Drug: DWRX2003, 960mg |
Phase 1 | Daewoong Pharmaceutical Co. LTD. | INDUSTRY | 24 | All | 19 Years ~ 55 Years | Chungnam National university hospital, Daejeon, Korea, Republic of |